Fluorizoline blocks the interaction between prohibitin-2 and γ-glutamylcyclotransferase, and induces p21\textsuperscript{Waf1/Cip1} expression in MCF7 breast cancer cells

Hiroko Takagi\textsuperscript{a,1}, Chiami Moyama\textsuperscript{a,1}, Keiko Taniguchi\textsuperscript{a,2}, Kota Ando\textsuperscript{a}, Ryohei Matsuda\textsuperscript{a}, Shota Ando\textsuperscript{a}, Hiromi Ii\textsuperscript{a}, Susumu Kageyama\textsuperscript{b}, Akihiro Kawauchi\textsuperscript{b}, Nora Chouha\textsuperscript{c}, Laurent Désaubry\textsuperscript{d,e}, Susumu Nakata\textsuperscript{a*}

Affiliations
\textsuperscript{a}Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashinaku, Kyoto 607-8414, Japan.
\textsuperscript{b}Department of Urology, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan.
\textsuperscript{c}University of Batna 2, Faculty of Biology, Batna, Algeria.
\textsuperscript{d}INSERM-University of Strasbourg, Regenerative Nanomedicine Laboratory (UMR1260), Faculty of Medicine, FMTS, Strasbourg, France.
\textsuperscript{e}Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.

\textsuperscript{1}These authors contributed equally to this work.
\textsuperscript{2}Current address: Department of Drug Discovery Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Keywords

Prohibitin-2, fluorizoline, $\gamma$-glutamylcyclotransferase, p21$^{WAF1/CIP1}$, cell cycle arrest, cancer
Running Title: Fluorizoline induces p21 via PHB2-GGCT interaction blockade

*Corresponding author. Susumu Nakata, Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashina-ku, Kyoto 607-8414, Japan. E-mail address: snakata@mb.kyoto-phu.ac.jp

Text pages: 30
Tables: 0
Figures: 8
References: 21
Abstract: 191
Introduction: 561
Discussion: 417

Abbreviations

PHB, prohibitin; GGCT, γ-glutamylcyclotransferase; p21, p21^{WAF1/CIP1}; qRT-PCR, quantitative real-time polymerase chain reaction; DMSO, dimethyl sulfoxide
Abstract

Prohibitin-2 (PHB2) is a scaffold protein that has pleiotropic functions, which include interacting with γ-glutamylcyclotransferase (GGCT) in the cytoplasm and repressing the transcriptional activities of the $p21^{Waf1/Cip}$ ($p21$) gene in the nucleus. The cytotoxic drug fluorizoline binds to PHB1/2 and exerts antiproliferative actions on cancer cells. However, the precise mechanism underlying the antiproliferative effects of fluorizoline is not fully elucidated. In the present study, we first show that fluorizoline induces $p21$ expression in several human cancer cell lines, including MCF7 breast cancer cells. Treatment of MCF7 cells with fluorizoline suppressed proliferation and prevented cells from entering into the DNA synthesis phase. Knockdown of $p21$ rescued the suppressed proliferation, indicating that fluorizoline inhibited MCF7 cell growth via the induction of $p21$. Overexpression of PHB2 in MCF7 cells prevented the induction of $p21$ expression by fluorizoline, and restored the antiproliferative effects and blockade of cell cycle progression. Moreover, treatment of MCF7 cells with fluorizoline inhibited the interaction between endogenous PHB2 and GGCT proteins, and reduced the level of nuclear localization of PHB2 proteins. These results indicate that targeting PHB2 with fluorizoline induces the expression of $p21$ and consequently blocks proliferation of cancer cells.

Significance Statement

This study shows that fluorizoline may be a promising novel anticancer drug candidate that induces $p21$ expression and blocks cell-cycle progression in...
human cancer cell lines. In addition, we show that fluorizoline inhibits the interaction between PHB2 and GGCT and reduces the nuclear localization of PHB2 proteins.
Introduction

Prohibitin-1 (PHB1) and -2 (PHB2) are scaffold proteins that have pleiotropic functions. These functions include the regulation of many cellular processes such as growth factor signaling pathways, the immune response, mitochondrial dynamics, cell migration, and transcriptional activities of estrogen receptor (Ande et al., 2017; Chowdhury et al., 2017; Koushyar et al., 2015; Peng et al., 2015; Theiss et al., 2011; Wang et al., 2020). PHB1/2 interact with various factors important for determining cell fate, such as C-RAF, Akt, IKK, MLK2, Shp1/2, and the 14-3-3 scaffold proteins. Due to the regulatory impact of PHB1/2 on cell proliferation, PHB1/2 are novel molecular targets for anticancer therapeutics (Wang et al., 2020).

To facilitate the development of a new class of anticancer drugs, several small molecules targeting PHB1/2 have been synthesized (Wang et al., 2020). An example of one promising molecule is fluorizoline, which directly binds to PHB1/2 and is cytotoxic to cancer cells (Pérez-Perarnau et al., 2014). Fluorizoline induces apoptosis in acute myeloid leukemia cells (Pomares et al., 2016) and chronic lymphocytic leukemia cells (Cosialls et al., 2017; Wierz et al., 2018), as well as in mouse embryonic fibroblasts and Hela cells, where this effect is mediated by upregulation of NOXA and BIM (Moncunill-Massaguer et al., 2015). In Hela cells, fluorizoline prevents activation of MEK1/2 upon EGF stimulation by disrupting the interaction between CRAF and active RAS (Yurugi et al., 2017). Moreover, fluorizoline inhibits protein synthesis in cancer cells due to its effects on multiple components of the translational machinery, including
promoting phosphorylation of initiation factor 2 (eIF2) and elongation factor 2 (eEF2) (Jin et al., 2020). Recently, it was confirmed that the cytotoxicity of fluorizoline in nematodes and human cancer cells requires the expression of PHB1/2 (Saura-Esteller et al., 2021). Despite these studies indicating the anticancer potential of fluorizoline, the precise mechanisms that underlie the antiproliferative effects of this compound are not fully understood.

Increasing evidence shows that γ-glutamylcyclotransferase (GGCT; formerly known as chromosome 7 open reading frame 24) promotes the proliferation of cancer cells. GGCT catalyzes the production of 5-oxoproline and free amino acids from gamma-glutamyl peptide to promote glutathione biosynthesis. It is highly expressed in a wide range of cancer types, including urothelial, breast, lung, brain, and ovary cancers (Kageyama et al., 2018). Knockdown or pharmaceutical inhibition of GGCT blocks proliferation of various human cancer cell lines. GGCT knockdown in MCF7 and MDA-MB-231 breast cancer cells upregulates the cyclin-dependent kinase inhibitors p21WAF1/CIP1 (p21) and/or p16INK4a to promote autophagy, followed by cellular senescence (Matsumura et al., 2016; Taniguchi et al., 2018a; Taniguchi et al., 2019).

Recently, we showed that PHB2 is a novel binding partner of GGCT (Taniguchi et al., 2018b). The interaction between PHB2 and GGCT promotes the nuclear translocation of PHB2, which binds to the promoter region of the p21 gene, thereby repressing transcription of the p21 gene in MCF7 breast cancer cells. The finding that PHB2 is a key regulator of the expression of p21, which is a pivotal cell cycle regulator and a downstream target of p53 (el-Deiry et al., 1993), led us to investigate the effects of fluorizoline on p21 expression in
cancer cells. In the present study, we show that fluorizoline induces p21 expression in several human cancer cell lines, and also demonstrate that fluorizoline suppresses cell cycle progression, blocks the interaction between PHB2 and GGCT, and inhibits the nuclear localization of PHB2 in MCF7 cells.
Materials and Methods

Cell culture

MCF7 human breast cancer, A172 glioblastoma, and PC3 prostate cancer cells were obtained from RIKEN BioResource Center (Tsukuba, Japan) and cultured in DMEM supplemented with 10% fetal bovine serum (HyClone, South Logan, UT, USA) and 1% penicillin and streptomycin. Cells were maintained in 5% CO\textsubscript{2} at 37°C.

Reagent

The PHB ligand fluorizoline was synthesized following an established procedure (Pérez-Perarnau et al., 2014) and dissolved in dimethyl sulfoxide (DMSO).

Cell proliferation assay

Briefly, 1 × 10\textsuperscript{5} MCF7, A172 and PC3 cells per well were seeded in 6-well plates and treated with fluorizoline at the indicated concentrations. A trypan blue dye exclusion test was performed using 0.4% trypan blue solution (Wako Pure Chemical Industries, Osaka, Japan) and a Countess II automated cell counter (Thermo Fisher Scientific, Waltham, MA, USA). Cell viability assays were performed using cell count reagent SF (WST-8 assay, Nacalai Tesque, Kyoto, Japan) and a CellTiter-Glo kit (Promega, Madison, WI, USA).

Antibodies
The following antibodies were used: mouse monoclonal antibodies specific for p21 (dilution 1:200, 556430, BD Biosciences, Franklin Lakes, NJ, USA), GAPDH (dilution 1:1000, 016-25523, Wako), the V5 epitope tag (V5) (dilution 1:1000, R960-25, Thermo Fisher Scientific), and PHB2 (dilution 1:200, Sc-133094, Santa Cruz Biotechnology, Dallas, TX, USA); a sheep monoclonal antibody against GGCT (dilution 1:500, AF5086, R&D systems, Minneapolis, MN, USA); and a rabbit monoclonal antibody against Lamin B1 (dilution 1:1000, 12987-I-AP, Proteintech, Rosemont, IL, USA). Horse anti-mouse IgG-HRP conjugates were purchased from Vector Laboratories (dilution 1:2000, PI-2000, Burlingame, CA, USA). Rabbit anti-sheep IgG-HRP conjugates were purchased from Thermo Fisher Scientific (dilution 1:5000, 81-8620). The HRP-linked goat anti-rabbit IgG (dilution 1:2000, 7074) and mouse IgG1 isotype controls (5415) were purchased from Cell Signaling Technology (Danvers, MA, USA). A mouse GGCT mouse monoclonal antibody (TSS-M01) was purchased from Cosmo Bio (Tokyo, Japan).

Western blot analysis

Western blot analysis was performed as described previously (Taniguchi et al., 2018b). Briefly, cell lysates were prepared in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor cocktail (Nacalai Tesque). The proteins were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Burlington, MA, USA). After blocking with 3% fat-free dried milk in TBS/0.05% Tween-20 (TBST), or PVDF blocking reagent for Can Get Signal
(TOYOBO, Osaka, Japan), the membranes were incubated with primary antibodies in 3% BSA/TBST, Can Get Signal immunoreaction enhancer solution (TOYOBO), or signal enhancer HIKARI solution (Nacalai Tesque). Proteins were visualized using the Clarity Western ECL substrate (Bio-Rad, Hercules, CA, USA) or Chemi-Lumi One Super (Nacalai Tesque) and were detected using the ChemiDoc XRS plus system (Bio-Rad).

Transfection of siRNA targeting p21

Synthesized siRNAs were purchased from RNAi (Tokyo, Japan) or Gene Design (Osaka, Japan). The siRNA sequences were as follows: non-targeting, 5’-GUACCGCAGUGUAUUCGU-3’ (sense) and 5’-UACGAUGACGGUGACGU-3’ (anti-sense); p21, 5’-CUUCGACUUGUCACCGAG-3’ (sense) and 5’-CUCGGUGACAAAGUGAAG-3’ (anti-sense). Transient transfection of siRNA targeting p21 was performed using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. Briefly, MCF7 and PC3 cells were seeded in 6-well plates (5 × 10⁴ cells / well), cultured for 24 h, and transfected with siRNAs at a concentration of 10 nM. At 24 h post-transfection, the cells were treated with fluorizoline 1 μM or 5 μM for 48 h, and then collected and analyzed with Western blot and cell counting as described above.

PHB2 overexpression

The procedure was carried out as described in (Taniguchi et al., 2018b). Briefly, the pENTR221-PHB2 vector (clone no. 10001434, DNAFORM,
Yokohama, Japan) was recombined into the pEF-DEST51 vector using a Gateway LR Clonase II enzyme mix (Thermo Fisher Scientific). Next, $2 \times 10^6$ MCF7 cells were transfected with 2 µg V5-tagged PHB2 vector or pEF-DEST51 empty vector by electroporation using an Amaza cell line Nucleofector kit V and a Nucleofector 2b device (Lonza, Visp, Switzerland) with a P-020 program optimized for MCF7 cells. DMEM containing 10 µg/ml blasticidin was used for clone selection.

**qRT-PCR analysis**

Total RNA was extracted from MCF7 cells lysed with TRizol (Thermo Fisher Scientific) and purified with an RNeasy mini kit (Qiagen, Hilden, Germany). cDNA was synthesized by reverse transcription using ReverTra Ace qPCR RT master mix (TOYOBO). Synthesized cDNA was analyzed by RT-qPCR with THUNDERBIRD SYBR qPCR mix (TOYOBO) using a LightCycler 96 system (Roche Diagnostic, Indianapolis, IN, USA). Gene expression levels were normalized against the housekeeping gene hARF1. Specific primers were purchased from Eurofins Genomics (Tokyo, Japan): hARF1, 5’-GACCACGATCCTCTACAAGC -3’ (forward) and 5’-TCCACACAGTGAAGCTGATG -3’ (reverse); p21WAF1/CIP1, 5’-GCAGACCACGATGACAGATTT-3’ (forward); 5’-GGATTAGGGCTTCTCTTGG-A3’ (reverse).

**BrdU incorporation assay**

MCF7 cells were treated with 1 µM fluorozoline for 24 h. The proportion
of MCF7 cells in the DNA synthesis phase was assessed after BrdU-pulse for 1.5 h using an APC BrdU flow kit (BD Biosciences) according to the manufacturer’s instructions. At least 10,000 cells per sample were analyzed.

**Cell cycle assay**

MCF7 cells or A172 cells were seeded at 1.5 x 10^5 cells in 6 cm dishes. The next day, the cells were treated with 1 µM or 5 µM fluorizoline for 24 h. The cells were harvested in PBS, and stained with a Cell Cycle Assay Solution Blue (Dojindo, Kumamoto, Japan). Cell cycle ratios of the stained cells were analyzed using FACS Fortessa (BD Biosciences).

**Apoptosis assay**

Apoptosis induction was assessed using the MEBCYTO Apoptosis Kit (MBL, Nagoya, Japan). Annexin V-positive and propidium iodide (PI)-negative cells in the early phase of apoptosis, Annexin V-positive and (PI)-positive cells in the late phase of apoptosis were detected by flow cytometry using a BD LSRFortessa X-20 cell Analyzer (BD Biosciences). At least 10,000 cells were analyzed for each experiment.

**Co-immunoprecipitation**

The antibody-bead complexes were prepared by incubating 10 µg anti-GGCT (6-1E, Cosmo Bio) or isotype control antibody with 1.5 mg Dynabeads protein G (Thermo Fisher Scientific). MCF7, A172 and PC3 cells were cultured in 10 cm dishes, treated with fluorizoline at the indicated
concentrations for the indicated durations, and then lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate-Na, and 0.1% SDS) supplemented with a protease inhibitor cocktail (Nacalai Tesque). Mixtures comprising cell lysate and each antibody-bead complex were rotated overnight at 4°C. After washing with PBS, the complexes were eluted in SDS-sample buffer, denatured at 95°C for 5 minutes, and analyzed by Western blotting.

**Fractionation of nuclear/cytoplasmic proteins**

MCF7, A172 and PC3 cells were treated with fluorizoline at the indicated concentrations for the indicated durations, and then cellular proteins were fractionated into cytoplasmic and nuclear fractions using a LysoPure nuclear and cytoplasmic extractor kit (Wako), according to the manufacturer’s protocol.

**Subcellular localization analysis of PHB2 proteins by immunofluorescent staining**

MCF7 cells were treated with fluorizoline for 24 h. The cells were fixed with 10%(v/v) formaldehyde in PBS for 30 min at room temperature. Then, permeabilization was performed using 0.5% triton-X 100 containing PBS for 15 min at 4 °C. After blocking with 0.1% triton-X 100, 1% BSA containing PBS for 45 min at room temperature, the cells were incubated in primary antibodies, anti-PHB2 antibody (dilution, 1:50) in Can Get Signal immunostain solution A (TOYOBO) for 1h at room temperature. Then cells were incubated in secondary antibodies, polyclonal rabbit anti-mouse Immunoglobulins FITC (Dako, Carpinteria, CA, USA) (dilution, 1:800) in Can Get Signal Immunostain Solution
A for 1h at room temperature. Nuclei were counterstained with 4, 6-Diamidino-2-phenylindole (DAPI) (Lonza Basel, Switzerland) in PBS for 5min at room temperature. Images were obtained with an Eclipse Ti confocal microscope (Nikon, Tokyo, Japan). Quantitative analysis of fluorescence of PHB2 in nuclei were performed by ImageJ 1.53k software (NIH, Bethesda, MD, USA).

Statistical analysis

All data were obtained from at least three independent experiments and expressed as the mean ± S.D. Statistical analysis was performed using a two-tailed Student’s t-test, one-way ANOVA with Bonferroni’s Multiple Comparison Test or 2-way repeated-measures ANOVA with BellCurve for Excel (Social Survey Research Information Co., Ltd. Tokyo, Japan). A p-value < 0.05 was deemed significant.
Results

**Fluorizoline inhibits MCF7 proliferation and induces p21 expression**

First, we examined the effects of fluorizoline treatment on the growth of MCF7 breast cancer cells. A trypan blue dye exclusion test demonstrated that treatment of MCF7 cells with fluorizoline for 24, 48 and 72 h suppressed cell growth in a concentration-dependent manner (Fig. 1A). We next examined whether fluorizoline treatment induces p21 expression. Western blot analyses demonstrated that treatment of MCF7 cells with fluorizoline for 24 h significantly increased p21 protein expression in a concentration-dependent manner (Fig. 1B). Fluorizoline also suppressed proliferation (Fig. 1A) and induced p21 expression (Fig. 1B) in A172 human glioblastoma and PC3 prostate cancer cells. A time-course analysis of 1 µM fluorizoline treatment in MCF7 cells showed that expression levels of p21 protein increased 3 h after treatment (Fig. 1C). A qRT-PCR analysis demonstrated that 1 µM fluorizoline significantly induced mRNA expression levels of p21 from 1 h treatment (Fig. 1D). These results indicate that fluorizoline induces p21 expression and inhibits proliferation of MCF7 breast cancer cells.

**Fluorizoline induces cell cycle arrest but not Apoptosis**

Cell cycle analysis revealed significant increases of the G0/G1 phase population and decreases of the S phase population with fluoizoline in MCF7 cells or A172 cells. However, no increase of sub G1 population in the cell-cycle analyses was observed (Fig. 2A-B). Furthermore, Annexin V positive cells were not observed.
in the fluoroizoline-treated MCF7 and A172 cells (data not shown). These results suggest that fluoroizoline does not induced apoptosis in MCF7 cells and A172 cells but mainly induced cell-cycle arrest.

*Induction of p21 mediates proliferative suppression of MCF7 cells by fluoroizoline*

Next, we performed knockdown of p21 in MCF7, A172 and PC3 cells to test whether inhibition of cell proliferation by fluoroizoline would be restored by suppression of p21. We confirmed the efficient knockdown of p21 by Western blot analysis (Fig. 3A). The p21 knockdown significantly rescued the suppressed proliferation of MCF7, A172 and PC3 cells by treatment with 1 µM or 5µM fluoroizoline for 48 h (Fig. 3B). These results indicate that fluoroizoline inhibits proliferation of MCF7 cells in a p21-induction dependent manner.

*Overexpression of PHB2 restores growth in fluoroizoline-treated MCF7 cells*

To confirm that fluoroizoline suppresses MCF7 cell proliferation by inhibiting PHB2 activity we prepared PHB2-overexpressing MCF7 cells and examined the effects of fluoroizoline. We confirmed the overexpressed PHB2 proteins by Western blot analysis (Fig. 4A). Assessments of proliferation in empty vector-transfected (Control) and PHB2-overexpressing (PHB2-OE) MCF7 cells treated with 0.1 µM or 1 µM fluoroizoline for 48h, the WST-8 cell viability assay showed PHB2 overexpression restored cell growth at 48 h (Fig. 4B). The ATP-based cell viability assay showed partially yet significantly restored cell growth in the PHB2-overexpressing MCF7 cells treated with 1 µM fluoroizoline for 24 h (Fig. 4C). Consistent with these findings, Western blot analyses
demonstrated that overexpression of PHB2 prevented the fluorizoline-mediated increase in p21 expression (Fig. 4D). These results suggest that fluorizoline increases p21 expression and suppresses cellular proliferation by modulating the activity PHB2.

**Overexpression of PHB2 restores cell cycle progression in fluorizoline-treated MCF7 cells**

Since p21 is an important regulator of the cell cycle, we next investigated the effects of fluorizoline on cell cycle progression in parental and PHB2-overexpressing MCF7 cells. A BrdU incorporation assay demonstrated that fluorizoline significantly reduced the number of MCF7 cells in S-phase, and that PHB2 overexpression partially but significantly restored cell cycle progression (Fig. 5A-B). These results indicate that fluorizoline suppresses the growth of MCF7 cells by inhibiting cell cycle progression, and this effect is associated with increases in p21 expression.

**Fluorizoline blocks the interaction between PHB2 and GGCT proteins and reduces the nuclear localization of PHB2**

PHB2 interacts with GGCT and the interaction promotes the nuclear localization of PHB2 proteins, which then bind to the promoter of the p21 gene and repress transcription (Taniguchi et al., 2018b). We finally investigated the effects of fluorizoline treatment on the interaction between PHB2 and GGCT proteins. Results of a co-immunoprecipitation assay using monoclonal antibodies against GGCT revealed that fluorizoline treatment blocked the interaction between
endogenous PHB2 and GGCT proteins (Fig. 6A). Consistent with the results, PHB2 protein expression in the insoluble nuclear fraction (Fig. 6B) and nuclear localization of PHB2 (Fig. 7A-B) were reduced after fluorizoline treatment. These results suggest that fluorizoline prevents PHB2 from interacting with GGCT, which then inhibits the nuclear localization of PHB2 proteins, resulted in the induction of p21 (Fig. 8).
Discussion

Here, we first show that fluorizoline induces p21 expression in human cancer cell lines. Our time-course analysis demonstrated that fluorizoline treatment as short as 1 h significantly increased the mRNA levels of p21, suggesting that fluorizoline directly influences p21 expression. Moreover, knockdown of p21, which prevented from its induction by fluorizoline treatment, significantly cancelled the proliferative inhibition of MCF7 cells by fluorizoline. We provide evidence from a co-immunoprecipitation assay showing that fluorizoline blocked the interaction between PHB2 and GGCT. A previous study demonstrated that the interaction between GGCT and PHB2 promotes the nuclear translocation of the PHB2 protein, which plays an important role in repressing p21 expression (Taniguchi et al., 2018b). Consistent with those findings, we show that fluorizoline treatment markedly reduces the amount of PHB2 protein in a chromatin-bound insoluble nuclear fraction; indeed, PHB2 protein could not be detected in this fraction even after long chemiluminescence exposure times in Western blot analysis. This meant it was not feasible to perform chromatin immunoprecipitation analysis following fluorizoline treatment using PHB2 antibodies because of the absence of the target PHB2 proteins.

Our findings showing that overexpression of PHB2 restored the cellular proliferation that was inhibited by fluorizoline indicate that fluorizoline targets PHB2. In particular, PHB2 overexpression prevented fluorizoline-mediated increases in p21 expression. The fluorizoline-mediated blockade of cell cycle progression was prevented by PHB2 overexpression, as shown by the BrdU
incorporation assay. These results also indicate that the effects of fluorizoline were mediated by p21 induction. However, recovery of proliferation and cell cycle arrest by PHB2 overexpression were partial, suggesting existence of other mechanisms for fluorizoline or potential involvement of PHB1 instead of PHB2. It has been reported that PHB2 exerts pleiotropic functions in the nucleus, where it acts as a transcriptional regulator binding to MyoD, MEF2, HDAC1/5, EZH2, RNF2, or estrogen receptors (Thuaud et al., 2013). Further clarification of the binding partner for PHB2 on the p21 promoter would provide useful information on the mechanisms that underly the complicated functions of PHB2.

Our findings show that fluorizoline induces p21 expression in several human cancer cell lines. The increase in p21 expression, antiproliferative effects, and blockade of cell cycle progression mediated by fluorizoline treatment were reversed by PHB2 overexpression, indicating that fluorizoline specifically targets PHB2. Fluorizoline inhibited the interaction between GGCT and PHB2, which decreased the nuclear localization of PHB2. Taken together, these results shed new light on the mechanism of action of fluorizoline and illustrate how this small molecule can be used to explore new aspects of PHB signaling.

Acknowledgments

We thank Momoka Endo for experimental support.

Authorship Contributions

Participated in research design: Kageyama, Kawauchi, Désaubry and Nakata.

Conducted experiments: Takagi, Moyama, Taniguchi, K. Ando, Matsuda, S.
Ando, Li and Chouha.

Performed data analysis: Takagi, Moyama, Taniguchi, K. Ando, Matsuda, S.
Ando, Li, Chouha, Désaubry and Nakata.

Wrote or contributed to the writing of the manuscript: Takagi, Moyama, Taniguchi, Désaubry and Nakata.
References


Koushyar S, Jiang WG and Dart DA (2015) Unveiling the potential of prohibitin in


Financial Disclosure

No author has an actual or perceived conflict of interest with the contents of this article.

Footnotes

This work was supported by the Japan Society for the Promotion of Science (grant numbers 18K09192 and 20K07623) and the Takeda Science Foundation, a Scholarship for Young/Women Researchers of the PMAC.
**Figure Legends**

**Fig. 1.** Fluorizoline inhibits MCF7 proliferation and induces p21 expression. MCF7, A172 and PC3 cells were treated with the indicated concentrations of fluorizoline for the indicated durations. (A) The number of trypan blue-negative viable cells is shown. The DMSO-treated solvent control is shown as a fluorizoline concentration of 0 nM (MCF7; n = 6, A172; n = 3, PC3; n = 3). (B) Concentration-dependent expression of p21 in MCF7, A172 and PC3 cells analyzed by Western blot analysis is shown. GAPDH is shown as a loading control. The time-course of p21 protein (C) and mRNA (D) expression levels in MCF7 cells were analyzed by Western blot analysis and qRT-PCR, respectively (n = 3). (*P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with Bonferroni’s Multiple Comparison Test).

**Fig. 2.** Fluorizoline induces cell cycle arrest. (A) MCF7 cells were treated with the 1 μM fluorizoline (or DMSO control) for 24 h, and the distribution of cell cycle phases were analyzed by flow cytometry. Representative histograms and quantified distributions are shown. (Control; n = 7, 1 μM; n = 9). (B) A172 cells were treated with the 1 μM or 5 μM fluorizoline (or DMSO control) for 24 h, and the distribution of cell cycle phases were analyzed by flow cytometry. Representative histograms and quantified distributions are shown. (Control; n = 6, 1 μM; n = 3, 5 μM; n = 3). (*P < 0.05, **P < 0.01 by two-tailed Student’s t-test).
**Fig. 3.** p21 knockdown restores cell proliferation suppressed by fluorizoline.

MCF7, A172 and PC3 cells were transfected with siRNA targeting p21 or non-target control siRNA and treated with the 1 μM or 5 μM fluorizoline for 48 h. (A) The expression levels of p21 protein were analyzed by Western blot analysis. GAPDH is shown as a loading control. (B) The number of trypan blue-negative viable cells is shown (MCF7: n = 3, A172: control siRNA; n = 11, p21 siRNA; n = 9, PC3: n = 6) (**P < 0.001 by 2-way repeated-measures ANOVA).

**Fig. 4.** PHB2 plays a crucial role in regulating changes in p21 expression and cell growth induced by fluorizoline treatment. (A) PHB2-overexpressing (PHB2-OE) or empty vector-transfected (Control) MCF7 cells were prepared, and expression levels of the introduced PHB2 proteins were analyzed by Western blotting. (B) The relative cell viability of control and PHB2-OE MCF7 cells treated with 0.1 or 1 μM fluorizoline (or DMSO control) was analyzed by a WST-8 cell viability assay (n = 5). (C) The relative cell viability of control and PHB2-OE MCF7 cells treated with 1 μM fluorizoline for 24 h was analyzed by CellTiter-Glo 2.0 luminescent cell viability assay (Control; n = 4, PHB2-OE; n = 5). (D) Western blot analysis of p21, V5 tag (linked to the C-terminus of overexpressed PHB2), and GAPDH in MCF7 cells 24 h after treatment with 1 μM fluorizoline. GAPDH is shown as a loading control. (*P < 0.05 by 2-way repeated-measures ANOVA)

**Fig. 5.** Fluorizoline-induced blockade of cell cycle progression is mediated by PHB2. (A) The fraction of control or PHB2-overexpressing (PHB2-OE) MCF7
cells in S-phase was measured by BrdU incorporation. PHB2-OE MCF7 cells treated with 1 µM fluorizoline for 24 h were measured by flow cytometry. (B) Quantitative analyses of the proportion of cells in S-phase (n = 4, ***P < 0.001 by 2-way repeated-measures ANOVA).

**Fig. 6.** Fluorizoline blocks the interaction between PHB2 and GGCT and decreases PHB2 protein levels in the nuclear fraction. (A) MCF7, A172 and PC3 cells were treated with fluorizoline at the indicated concentrations for the indicated durations. Endogenous GGCT proteins were immunoprecipitated (IP) from cell extracts using mouse anti-GGCT monoclonal or isotype control antibodies. PHB2 and GGCT proteins in the precipitated samples (and lysate input) were analyzed by Western blotting (WB). (B) The proteins were fractionated into cytoplasmic, soluble nuclear, and insoluble nuclear components and were analyzed by WB. Lamin B1 and GAPDH are shown as loading controls.

**Fig. 7.** Fluorizoline reduces the nuclear localization of PHB2. (A) MCF7 cells were treated with 1 µM fluorizoline for 24 h. Immunofluorescent analysis was performed using anti-PHB2 (green) antibody and DAPI (blue). Scale bar, 50 µm. (B) Quantified analysis of fluorescent signal of PHB2 in nuclei are shown. (n = 9, ***P < 0.001 by two-tailed Student's t-test).

**Fig. 8.** Fluorizoline disrupts the interaction of PHB2 with GGCT and its translocation into the nucleus, resulting in an upregulation of p21 and a blockade
of cell cycle progression in MCF7 cells.
**Fig. 4**

**A**

<table>
<thead>
<tr>
<th></th>
<th>PHB2</th>
<th>GAPDH</th>
<th>PHB2-OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 μM</td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>1.5 μM</td>
<td></td>
<td></td>
<td>+</td>
</tr>
</tbody>
</table>

**B**

**Control MCF7**
- DMSO control
- fluorizoline 0.1 μM
- fluorizoline 1 μM

**PHB2-OE MCF7**
- DMSO control
- fluorizoline 0.1 μM
- fluorizoline 1 μM

**Relative cell viability**

<table>
<thead>
<tr>
<th></th>
<th>48 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 μM</td>
<td>1</td>
</tr>
<tr>
<td>1.5 μM</td>
<td>2</td>
</tr>
</tbody>
</table>

**C**

**Luminescent intensity (x10^5)**

<table>
<thead>
<tr>
<th>Fluorizoline (1 μM, 24 h)</th>
<th>PHB2-OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**D**

**p21 V5 (PHB2-OE)**

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>2.9</th>
<th>2.3</th>
<th>1.5</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GAPDH**

<table>
<thead>
<tr>
<th>Fluorizoline (1 μM, 24 h)</th>
<th>PHB2-OE</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Downloaded from molpharm.aspetjournals.org on August 8, 2022.
Fig. 5

A

Control MCF7

PHB2-OE MCF7

DMSO

33.5%  33.0%

35.4%  39.4%

15.1%  9.5%

Fluorozoline (1 μM, 24 h)

Control MCF7

PHB2-OE MCF7

22.6%  27.3%

40.6%  48.7%

18.1%  11.1%

7-AAD

B

Ratio of DNA synthesis phase cells

(%)
Fig. 7

A

FITC (PHB2) + DAPI

DMSO

Fluorizoline (1 μM)

FITC (PHB2)

B

Relative fluorescence in nuclei

fluorizoline (1 μM, 24 h)

*